18Apr 2024
argenx SE's VYVGART® Hytrulo Shows a Potential Breakthrough for Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE's VYVGART® Hytrulo Shows a Potential Breakthrough for Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE has unveiled promising data from its Phase 3 ADHERE trial, showcasing VYVGART® Hytrulo's potential as a groundbreaking treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). Presented at the American Academy of Neurology (AAN) Annual Meeting, the study highlights rapid clinical improvements and a significant reduction in relapse risk with VYVGART Hytrulo compared to a placebo. Furthermore, real-world data suggest a significant reduction of steroid use among generalized myasthenia gravis (gMG) patients following VYVGART treatment. The FDA is anticipated to make a decision on VYVGART Hytrulo for CIDP treatment by June 21, 2024.

  • #family health

Like

Save

Share